-transparent.png){kind=logo}
[All-trans retinoic acid combined with low-dose cytosine arabinoside treatment for acute myelogenous leukemia with trilineage myelodysplasia--a case report]. 2001
N Maeda, and
S Satake, and
Y Okada, and
S Asahara, and
N Hasuike, and
M Tamura, and
M Takata, and
K Tasaka, and
T Okutani, and
Y Maeda, and
Y Tomofuji, and
T Chinzei, and
K Saigo
Dept. of Internal Medicine, Kakogawa Municipal Hospital.
AML with trilineage myelodysplasia (AML/TMDS) is recognized as having of poor prognosis due to its resistance to chemotherapy in comparison with de novo AML. An AML/TMDS patient who failed to respond to ordinary induction therapy achieved complete remission with combination therapy consisting of all-trans retinoic acid (ATRA) and low-dose Ara-C. No serious toxicity was observed. ATRA combined with low-dose Ara-C could be an alternative treatment for this kind of patient.
Related Publications
N Maeda, and
S Satake, and
Y Okada, and
S Asahara, and
N Hasuike, and
M Tamura, and
M Takata, and
K Tasaka, and
T Okutani, and
Y Maeda, and
Y Tomofuji, and
T Chinzei, and
K Saigo
August 1987,
Leukemia,
N Maeda, and
S Satake, and
Y Okada, and
S Asahara, and
N Hasuike, and
M Tamura, and
M Takata, and
K Tasaka, and
T Okutani, and
Y Maeda, and
Y Tomofuji, and
T Chinzei, and
K Saigo
July 1995,
Leukemia,
N Maeda, and
S Satake, and
Y Okada, and
S Asahara, and
N Hasuike, and
M Tamura, and
M Takata, and
K Tasaka, and
T Okutani, and
Y Maeda, and
Y Tomofuji, and
T Chinzei, and
K Saigo
December 1987,
Chinese medical journal,
N Maeda, and
S Satake, and
Y Okada, and
S Asahara, and
N Hasuike, and
M Tamura, and
M Takata, and
K Tasaka, and
T Okutani, and
Y Maeda, and
Y Tomofuji, and
T Chinzei, and
K Saigo
March 1998,
British journal of haematology,
N Maeda, and
S Satake, and
Y Okada, and
S Asahara, and
N Hasuike, and
M Tamura, and
M Takata, and
K Tasaka, and
T Okutani, and
Y Maeda, and
Y Tomofuji, and
T Chinzei, and
K Saigo
March 1998,
Leukemia & lymphoma,
N Maeda, and
S Satake, and
Y Okada, and
S Asahara, and
N Hasuike, and
M Tamura, and
M Takata, and
K Tasaka, and
T Okutani, and
Y Maeda, and
Y Tomofuji, and
T Chinzei, and
K Saigo
January 2007,
American journal of therapeutics,
N Maeda, and
S Satake, and
Y Okada, and
S Asahara, and
N Hasuike, and
M Tamura, and
M Takata, and
K Tasaka, and
T Okutani, and
Y Maeda, and
Y Tomofuji, and
T Chinzei, and
K Saigo
May 2003,
Leukemia & lymphoma,
N Maeda, and
S Satake, and
Y Okada, and
S Asahara, and
N Hasuike, and
M Tamura, and
M Takata, and
K Tasaka, and
T Okutani, and
Y Maeda, and
Y Tomofuji, and
T Chinzei, and
K Saigo
November 1999,
Leukemia & lymphoma,
N Maeda, and
S Satake, and
Y Okada, and
S Asahara, and
N Hasuike, and
M Tamura, and
M Takata, and
K Tasaka, and
T Okutani, and
Y Maeda, and
Y Tomofuji, and
T Chinzei, and
K Saigo
February 1994,
American journal of hematology,
N Maeda, and
S Satake, and
Y Okada, and
S Asahara, and
N Hasuike, and
M Tamura, and
M Takata, and
K Tasaka, and
T Okutani, and
Y Maeda, and
Y Tomofuji, and
T Chinzei, and
K Saigo
June 1987,
Zhonghua nei ke za zhi,
